430 related articles for article (PubMed ID: 36903645)
21. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
[TBL] [Abstract][Full Text] [Related]
22. Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis.
Garg N; Padron EJ; Rammohan KW; Goodman CF
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294458
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis.
Kong W; Deng W; Sun Y; Huang S; Zhang Z; Shi B; Chen W; Tang X; Yao G; Feng X; Sun L
Clin Rheumatol; 2018 Jan; 37(1):43-49. PubMed ID: 28612243
[TBL] [Abstract][Full Text] [Related]
24. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
25. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C
Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834
[TBL] [Abstract][Full Text] [Related]
26. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
27. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
[TBL] [Abstract][Full Text] [Related]
28. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
Liu J; Chen C; Wang D; Zhang J; Zhang T
Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
[TBL] [Abstract][Full Text] [Related]
29. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
[TBL] [Abstract][Full Text] [Related]
30. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
31. Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer cell invasion via PLCγ2/PKCβ/NF‑κB/AP‑1‑dependent matrix metalloproteinase‑9 activation.
Kim JM; Park J; Noh EM; Song HK; Kang SY; Jung SH; Kim JS; Park BH; Lee YR; Youn HJ
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760219
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547
[TBL] [Abstract][Full Text] [Related]
33. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
[TBL] [Abstract][Full Text] [Related]
34. Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases.
Guo Y; Hu N; Liu Y; Zhang W; Yu D; Shi G; Zhang B; Yin L; Wei M; Yuan X; Luo L; Wang F; Song X; Xin L; Wei Q; Li Y; Guo Y; Chen S; Zhang T; Zhang S; Zhou X; Zhang C; Su D; Liu J; Cheng Z; Zhang J; Xing H; Sun H; Li X; Zhao Y; He M; Wu Y; Guo Y; Sun X; Tian A; Zhou C; Young S; Liu X; Wang L; Wang Z
J Med Chem; 2023 Mar; 66(6):4025-4044. PubMed ID: 36912866
[TBL] [Abstract][Full Text] [Related]
35. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
36. Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.
Arneson LC; Carroll KJ; Ruderman EM
Immunotargets Ther; 2021; 10():333-342. PubMed ID: 34485183
[TBL] [Abstract][Full Text] [Related]
37. Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies.
Neys SFH; Hendriks RW; Corneth OBJ
Front Cell Dev Biol; 2021; 9():668131. PubMed ID: 34150760
[TBL] [Abstract][Full Text] [Related]
38. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
39. Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE; Brown JR
Front Immunol; 2021; 12():687458. PubMed ID: 34248972
[TBL] [Abstract][Full Text] [Related]
40. Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
Lorenzo-Vizcaya A; Fasano S; Isenberg DA
Immunotargets Ther; 2020; 9():105-110. PubMed ID: 32582577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
